| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -6.6 | -3.0 |
| Net income | -6.6 | -3.0 |
| EPS (diluted, $ a share) | $-0.20 | $-0.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KTTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pasithea Therapeutics Corp.: key numbers
- Share price
- $0.5000Close, Nov 16
- Market cap
- $18.4M
- Shares outstanding
- 36.75MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pasithea Therapeutics Corp.
All →Pasithea Therapeutics Clinical Trial Data
Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.
Pasithea Therapeutics Other 8-K Filing
Pasithea Therapeutics Corp. announced that its warrants (KTTAW) will expire on September 17, 2026, and will subsequently be delisted from The Nasdaq Capital Market. Any warrants not exercised prior to the expiration date will cease to be exercisable and will have no further value. The company's common stock (KTTA) will continue to trade on Nasdaq.